3-溴-4-氟苯乙烯酸 | 160434-49-1

• 物质功能分类: 香精与香料 - 合成香料 - 芳香肉桂酸、酯及衍生物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 3-溴-4-氟苯乙烯酸
• 中文别名: 3-溴-4-氟肉桂酸
• 英文名称: 3-(3-bromo-4-fluorophenyl)acrylic acid
• 英文别名: 3-(3-bromo-4-fluorophenyl)prop-2-enoic acid
• CAS: 160434-49-1
• 化学式: C₉H₆BrFO₂
• 分子量: 245.048
• InChiKey: ZNIGVADAKXOMQH-UHFFFAOYSA-N

物化性质

• 熔点：
  189-192 °C
• 沸点：
  337.4±32.0 °C(Predicted)
• 密度：
  1.6228 (rough estimate)
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S28A
• 危险类别码：
  R36/37/38
• 海关编码：
  29163990
• 危险性防范说明：
  P261,P305+P351+P338,P302+P352,P321,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Name:	3-Bromo-4-Fluorocinnamic Acid 99+% Material Safety Data Sheet
Synonym:	None known
CAS:	160434-49-1

Section 1 - Chemical Product MSDS Name:3-Bromo-4-Fluorocinnamic Acid 99+% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
160434-49-1	3-Bromo-4-Fluorocinnamic Acid	99+	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 160434-49-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 189.00 - 191.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: insoluble
Specific Gravity/Density:
Molecular Formula: C9H6BrFO2
Molecular Weight: 245.05

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen fluoride gas, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 160434-49-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Bromo-4-Fluorocinnamic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 37/39 Wear suitable gloves and eye/face
protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 160434-49-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 160434-49-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 160434-49-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

化学试剂、有机中间体、精细化学品、药物研发

用途简介

暂无内容

用途

化学试剂、有机中间体、精细化学品、药物研发

反应信息

• 作为反应物：
  描述：

  3-溴-4-氟苯乙烯酸 在 吡啶 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 生成 3-(3-bromo-4-fluorophenyl)-N-methoxy-N-methylacrylamide
  参考文献：
  名称：

  4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  本发明提供了一种4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐，以及其制备方法和包含该衍生物的药物组合物。4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐有效增加LXR转录活性，因此可以有效地用于预防或治疗胆固醇代谢功能障碍，如胆固醇结石、高脂血症或冠状动脉粥样硬化。

  公开号：

  US20150291563A1
• 作为产物：
  描述：

  丙二酸 、 3-溴-4-氟苯甲醛 在 哌啶 、 吡啶 作用下， 反应 3.0h， 以3.3 g的产率得到3-溴-4-氟苯乙烯酸
  参考文献：
  名称：

  4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  本发明提供了一种4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐，以及其制备方法和包含该衍生物的药物组合物。4,5-二氢-1H-吡唑烷衍生物或其药用可接受盐有效增加LXR转录活性，因此可以有效地用于预防或治疗胆固醇代谢功能障碍，如胆固醇结石、高脂血症或冠状动脉粥样硬化。

  公开号：

  US20150291563A1

文献信息

• Synthesis and Anti-influenza Activities of Novel Baicalein Analogs
  作者：Shu-Ting Chung、Pei-Yu Chien、Wen-Hsin Huang、Chen-Wen Yao、An-Rong Lee

  DOI：10.1248/cpb.c13-00897

  日期：——

  A series of novel flavones derivatives were synthesized based on modification of the active ingredients of a traditional Chinese medicine Scutellaria baicalensis GEORGI and screened for anti-influenza activity. The synthetic baicalein (flavone) analogs, especially with the B-rings substituted with bromine atoms, were much more potent than oseltamivir or ribavirin against H1N1 Tamiflu-resistant (H1N1 TR) virus and usually with more favorable selectivity. The most promising were 5b, 5c, 6b and 6c, all displaying an 50% effective concentration (EC50) at around 4.0–4.5 µM, and a selective index (SI=50% cytotoxic concentration (CC50)/EC50)>70. For seasonal H3N2-infected influenza virus, both 5a and 5b with SI >17.3 indicated superior to ribavirin. The flavonoids having both not-naturally-occurring bromo-substituted B-rings and appropriate hydroxyls positioning on the A-rings might be critical in determining the activity and selectivity against H1N1-Tamiflu-resistant infected influenza viruses.

  一系列新型黄酮衍生物是基于对传统中药黄芩（Scutellaria baicalensis GEORGI）活性成分的修饰合成的，并进行了抗流感活性筛选。合成的大黄素（黄酮）类似物，特别是B环上带有溴原子取代的类似物，对H1N1达菲耐药（H1N1 TR）病毒的活性远超奥司他韦或利巴韦林，并且通常具有更优越的选择性。最有希望的化合物是5b、5c、6b和6c，它们的50%有效浓度（EC50）都在4.0–4.5 µM左右，选择指数（SI=50%细胞毒性浓度（CC50）/EC50）>70。对于季节性H3N2流感病毒感染，5a和5b的SI均大于17.3，优于利巴韦林。这些具有非天然溴取代B环和A环上适当羟基位置的黄酮类化合物可能在决定抗H1N1达菲耐药流感病毒的活性和选择性方面起关键作用。
• Rhodium(<scp>i</scp>)-catalyzed C6-selective C–H alkenylation and polyenylation of 2-pyridones with alkenyl and conjugated polyenyl carboxylic acids
  作者：Haoqiang Zhao、Xin Xu、Zhenli Luo、Lei Cao、Bohan Li、Huanrong Li、Lijin Xu、Qinghua Fan、Patrick J. Walsh

  DOI：10.1039/c9sc03672e

  日期：——

  and is tolerant of a broad range of functional groups. A wide scope of alkenyl carboxylic acids, including challenging conjugated polyene carboxylic acids, are amenable to this transformation and no addition of external oxidant is required. Mechanistic studies revealed that (1) Boc2O acts as the activator for the in situ transformation of the carboxylic acids into anhydrides before oxidative addition

  已经开发了一种通用的 Rh(i) 催化的 C6 选择性脱羰基 CH 烯基化 2-吡啶酮，其具有现成的、廉价的烯基羧酸。这种定向的脱氢交叉偶联反应提供了 6-烯基化的 2-吡啶酮，否则使用传统的 CH 官能化方案难以获得。该反应以高效率发生并且对广泛的官能团具有耐受性。范围广泛的烯基羧酸，包括具有挑战性的共轭多烯羧酸，都适用于这种转变，并且不需要添加外部氧化剂。机理研究表明，（1）Boc2O 在 Rh 催化剂氧化加成之前作为羧酸原位转化为酸酐的活化剂，
• Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
  申请人：Galderma Research & Development, S.N.C.

  公开号：US20040092594A1

  公开（公告）日：2004-05-13

  Novel pharmaceutically/cosmetically-active bicyclic aromatic compounds have the structural formula. (I): 1 in which Ar 1 is a radical having one of the structural formulae (a)-(c): 2 Ar 2 is a radical having one of the following formulae (d)-(h): 3 and X is a radical having one of the following formulae (i)-(l): 4 and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

  具有药用/化妆品活性的双环芳香化合物具有结构式（I）：1其中Ar1是具有结构式（a）-（c）之一的基团：2Ar2是具有以下式（d）-（h）之一的基团：3而X是具有以下式（i）-（l）之一的基团：4并且对于治疗各种疾病状态（无论是人类还是兽医），例如皮肤病，风湿病，呼吸系统疾病，心血管疾病和眼科疾病以及哺乳动物皮肤和毛发状况/疾病的治疗非常有用。
• 8-substituted styryl xanthine derivatives
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05670498A1

  公开（公告）日：1997-09-23

  Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen or lower alkyl; Q.sup.1, Q.sup.2, and Q.sup.3 independently represent hydrogen, lower alkyl, lower alkoxy, or halogen; and X represents --COR.sup.4 (in which R.sup.4 represents hydrogen, hydroxy, lower alkyl, or lower alkoxy) or --SO.sub.2 R.sub.5 in which R.sup.5 represents hydroxy, lower alkoxy, trifluoromethyl, ##STR2## in which R.sup.6 and R.sup.7 independently represent hydrogen, hydroxy-substituted or unsubstituted lower alkyl, aryl, or ##STR3## (in which m represents an integer of 1 to 3; and R.sup.8 and R.sup.9 independently represent hydrogen or lower alkyl), or ##STR4## (in which Y represents a single bond, oxygen, or N--R.sup.10 in which R.sup.10 represents hydrogen or lower alkyl; and n1 and n2 independently represent an integer of 1 to 3)}, and pharmaceutically acceptable salts thereof.

  本发明涉及一种黄嘌呤衍生物，其化学式如下（I）：##STR1## 其中R.sup.1、R.sup.2和R.sup.3独立地表示氢或低碳基；Q.sup.1、Q.sup.2和Q.sup.3独立地表示氢、低碳基、低烷氧基或卤素；X表示--COR.sup.4（其中R.sup.4表示氢、羟基、低碳基或低烷氧基）或--SO.sub.2R.sub.5 其中R.sup.5表示羟基、低烷氧基、三氟甲基、##STR2## 其中R.sup.6和R.sup.7独立地表示氢、羟基取代或未取代的低碳基、芳基或##STR3## （其中m表示1至3的整数；R.sup.8和R.sup.9独立地表示氢或低碳基），或##STR4## （其中Y表示单键、氧或N--R.sup.10，其中R.sup.10表示氢或低碳基；n1和n2独立地表示1至3的整数）以及其药学上可接受的盐。
• AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Pajouhesh Hassan

  公开号：US20080227823A1

  公开（公告）日：2008-09-18

  Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both a diamide and aromatic functionality are disclosed of the general formula (1) where X 1 and X 2 are linkers.

  本发明揭示了对缓解具有不需要的钙通道活性，特别是不需要的T型钙通道活性所表征的状况有效的方法和化合物。具体来说，揭示了一系列含有二酰胺和芳香基功能的化合物，其通式为（1），其中X1和X2为连接物。